예방 백신 시장 보고서(2026년)

Preventive vaccines are biological products developed to protect individuals against infectious diseases by activating the immune system to identify and combat specific pathogens. They are given prior to exposure to disease-causing agents to prevent infection or lessen disease severity. Preventive vaccines are essential to public health efforts, as they help control and limit the spread of contagious illnesses.

The main types of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines are produced using weakened forms of viruses or bacteria that trigger a strong and long-lasting immune response without causing illness. These vaccines target diseases such as pneumococcal infections, poliovirus, hepatitis, influenza, measles, rubella, and others. Distribution channels include hospitals, clinics, pharmacies, and other healthcare facilities, and the vaccines are administered across pediatric, adult, and geriatric age groups.

Tariffs have impacted the preventive vaccines market by increasing costs associated with imported raw materials, bioreactors, and cold chain equipment used in vaccine manufacturing and distribution. Live and recombinant vaccines are particularly affected due to their complex production requirements, with regions such as Asia-Pacific and Latin America facing higher cost pressures. These challenges can influence pricing and supply timelines; however, tariffs have also encouraged domestic vaccine manufacturing, capacity expansion, and regional self-sufficiency, supporting long-term market stability.

The preventive vaccines market research report is one of a series of new reports from The Business Research Company that provides preventive vaccines market statistics, including preventive vaccines industry global market size, regional shares, competitors with a preventive vaccines market share, detailed preventive vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the preventive vaccines industry. This preventive vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preventive vaccines market size has grown strongly in recent years. It will grow from $83 billion in 2025 to $90.33 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to eradication and control of infectious diseases, government-led vaccination initiatives, rising public health awareness, establishment of global immunization programs, increased funding from international health organizations.

The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $131.27 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to development of next-generation vaccine platforms, rising global population and urbanization, increasing outbreak preparedness initiatives, expansion of adult immunization programs, growth in public-private partnerships in vaccine development. Major trends in the forecast period include expansion of national immunization programs, rising focus on preventive healthcare and disease control, increasing demand for pediatric and geriatric vaccination, growth in combination and multivalent vaccines, strengthening cold chain and vaccine storage infrastructure.

The rising prevalence of infectious diseases is anticipated to drive the growth of the preventive vaccines market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread between individuals or through environmental exposure. The increase in infectious disease prevalence is fueled by factors including rapid urbanization, increased global travel, and the growing challenge of antimicrobial resistance, all of which contribute to faster transmission and more difficult disease control. Preventive vaccines play a critical role in managing infectious diseases by activating the immune system to identify and combat pathogens before infection occurs, thereby lowering disease incidence and transmission rates. For instance, in 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, the number of newly diagnosed tuberculosis (TB) cases globally reached 8.2 million in 2023, rising from 7.5 million cases in 2022. Therefore, the increasing prevalence of infectious diseases is fueling the growth of the preventive vaccines market.

Major companies operating in the preventive vaccines market are emphasizing technological advancements, such as next-generation mRNA technology platforms, to improve vaccine effectiveness, enhance safety profiles, accelerate development and production timelines, and provide broader protection against emerging infectious disease variants. Advanced mRNA technology platforms utilize messenger RNA to instruct cells to produce specific antigens, thereby generating a targeted immune response. For example, in March 2025, Moderna Inc., a US-based biotechnology company, announced U.S. Food and Drug Administration approval for mRNA-1283 (mNEXSPIKE), a next-generation COVID-19 vaccine. This vaccine is approved for adults aged 65 years and older, as well as individuals aged 12 to 64 with one or more CDC-defined risk factors. The introduction of mNEXSPIKE represents a major advancement in mRNA vaccine technology, offering improved stability and simpler storage requirements compared to earlier formulations, which is expected to enhance vaccine accessibility and distribution, particularly in remote and underserved regions.

In April 2024, European LifeCare Group, a UK-based vaccination services company, acquired PreventVaccins B.V. for an undisclosed amount. Through this acquisition, European LifeCare Group strengthened its European presence and expanded its vaccination services by enhancing operations in the Netherlands. PreventVaccins B.V. is a Netherlands-based biotechnology company focused on the development of preventive vaccines, particularly for infectious diseases.

Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the preventive vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preventive Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses preventive vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preventive vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preventive vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Live Or Attenuated Vaccines; Inactivated Vaccines; Toxoid Vaccines; Subunit Vaccines; Conjugate Vaccines; DNA Vaccines; Recombinant Vector Vaccines
• 2) By Disease Type: Pneumococcal; Poliovirus; Hepatitis; Influenza; Measles; Rubella; Other Disease Types
• 3) By Age Group: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine; Varicella (Chickenpox) Vaccine; Oral Polio Vaccine (OPV); Yellow Fever Vaccine; Rotavirus Vaccine; Bacillus Calmette-Guerin (BCG) Vaccine
• 2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV); Hepatitis A Vaccine; Rabies Vaccine; Influenza (Inactivated) Vaccine; Japanese Encephalitis Vaccine
• 3) By Toxoid Vaccines: Tetanus Toxoid Vaccine; Diphtheria Toxoid Vaccine; Pertussis (whooping cough) Vaccine
• 4) By Subunit Vaccines: Hepatitis B Vaccine; Human Papillomavirus (HPV) Vaccine; Pertussis (acellular) Vaccine; Influenza (recombinant protein) Vaccine
• 5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV); Haemophilus influenzae type b (Hib) Vaccine; Meningococcal Conjugate Vaccine
• 6) By DNA Vaccines: Zika Virus DNA Vaccine; Cytomegalovirus (CMV) DNA Vaccine; Infectious Disease DNA Vaccines
• 7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV); COVID-19 Recombinant Vector Vaccines; Dengue Recombinant Vector Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Sanofi Pasteur SA; AstraZeneca plc; GlaxoSmithKline plc (GSK); Takeda Pharmaceutical Company Limited; Moderna Inc.; CSL Limited; Novavax Inc.; Emergent BioSolutions Inc.; Dynavax Technologies Corporation; Serum Institute of India Pvt. Ltd.; Vaxcyte Inc.; Bavarian Nordic A/S; Valneva SE; Panacea Biotec Ltd.; Inovio Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Afrigen Biologics and Vaccines (Pty) Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Preventive Vaccines Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Preventive Vaccines Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Preventive Vaccines Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Preventive Vaccines Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expansion Of National Immunization Programs
  • 4.2.2 Rising Focus On Preventive Healthcare And Disease Control
  • 4.2.3 Increasing Demand For Pediatric And Geriatric Vaccination
  • 4.2.4 Growth In Combination And Multivalent Vaccines
  • 4.2.5 Strengthening Cold Chain And Vaccine Storage Infrastructure

5. Preventive Vaccines Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Public Health Organizations
• 5.4 Vaccination Centers
• 5.5 Pharmacies

6. Preventive Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Preventive Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Preventive Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Preventive Vaccines Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Preventive Vaccines Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Preventive Vaccines Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Preventive Vaccines Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Preventive Vaccines Market Segmentation

• 9.1. Global Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
• 9.2. Global Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types
• 9.3. Global Preventive Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pediatric, Adult, Geriatric
• 9.4. Global Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Pharmacies, Other Distribution Channels
• 9.5. Global Preventive Vaccines Market, Sub-Segmentation Of Live Or Attenuated Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guerin (BCG) Vaccine
• 9.6. Global Preventive Vaccines Market, Sub-Segmentation Of Inactivated Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine
• 9.7. Global Preventive Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine
• 9.8. Global Preventive Vaccines Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine
• 9.9. Global Preventive Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine
• 9.10. Global Preventive Vaccines Market, Sub-Segmentation Of DNA Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines
• 9.11. Global Preventive Vaccines Market, Sub-Segmentation Of Recombinant Vector Vaccines, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines

10. Preventive Vaccines Market Regional And Country Analysis

• 10.1. Global Preventive Vaccines Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Preventive Vaccines Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Preventive Vaccines Market

• 11.1. Asia-Pacific Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Preventive Vaccines Market

• 12.1. China Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Preventive Vaccines Market

• 13.1. India Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Preventive Vaccines Market

• 14.1. Japan Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Preventive Vaccines Market

• 15.1. Australia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Preventive Vaccines Market

• 16.1. Indonesia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Preventive Vaccines Market

• 17.1. South Korea Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Preventive Vaccines Market

• 18.1. Taiwan Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Preventive Vaccines Market

• 19.1. South East Asia Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Preventive Vaccines Market

• 20.1. Western Europe Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Preventive Vaccines Market

• 21.1. UK Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Preventive Vaccines Market

• 22.1. Germany Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Preventive Vaccines Market

• 23.1. France Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Preventive Vaccines Market

• 24.1. Italy Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Preventive Vaccines Market

• 25.1. Spain Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Preventive Vaccines Market

• 26.1. Eastern Europe Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Preventive Vaccines Market

• 27.1. Russia Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Preventive Vaccines Market

• 28.1. North America Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Preventive Vaccines Market

• 29.1. USA Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Preventive Vaccines Market

• 30.1. Canada Preventive Vaccines Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Preventive Vaccines Market

• 31.1. South America Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Preventive Vaccines Market

• 32.1. Brazil Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Preventive Vaccines Market

• 33.1. Middle East Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Preventive Vaccines Market

• 34.1. Africa Preventive Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Preventive Vaccines Market, Segmentation By Type, Segmentation By Disease Type, Segmentation By Age Group, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Preventive Vaccines Market Regulatory and Investment Landscape

36. Preventive Vaccines Market Competitive Landscape And Company Profiles

• 36.1. Preventive Vaccines Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Preventive Vaccines Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Preventive Vaccines Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi Pasteur SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. Preventive Vaccines Market Other Major And Innovative Companies

• GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.

38. Global Preventive Vaccines Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Preventive Vaccines Market

40. Preventive Vaccines Market High Potential Countries, Segments and Strategies

• 40.1 Preventive Vaccines Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Preventive Vaccines Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Preventive Vaccines Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer